Cancer chemopreventive in vitro activities of isoflavones isolated from Iris germanica

Planta Medica

Volumn 69, Issue 1, 2003, Pages 15-20

  Wollenweber, Eckhard ^a   Stevens, Jan Frederik ^b,d   Klimo, Karin ^c   Knauft, Jutta ^c   Frank, Norbert ^c   Gerhäuser, Clarissa ^c  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b OREGON STATE UNIVERSITY   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

Cancer chemoprevention; Carcinogen metabolism; Iridaceae; Iris germanica; Isoflavones

Indexed keywords

4' HYDROXY 5,3' DIMETHOXY 6,7 METHYLENEDIOXYISOFLAVONE; 5,4' DIHYDROXY 3' METHOXY 6,7 METHYLENEDIOXYISOFLAVONE; 5,4' DIHYDROXY 6,7 METHYLENEDIOXYISOFLAVONE; 5,7 DIHYDROXY 6,4' DIMETHOXYISOFLAVONE; 5,7,3' TRIHYDROXY 6,4',5' TRIMETHOXYISOFLAVONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 INHIBITOR; CYTOCHROME REDUCTASE; IRIS GERMANICA EXTRACT; ISOFLAVONE DERIVATIVE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IRIS GERMANICA; MASS SPECTROMETRY; MEDICINAL PLANT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOOXYGENASE 1; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; ENZYME INHIBITORS; IRIS PLANT; ISOENZYMES; ISOFLAVONES; MEMBRANE PROTEINS; MICE; NAD(P)H DEHYDROGENASE (QUINONE); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; TUMOR CELLS, CULTURED;

ANIMALIA; IRIDACEAE; IRIS GERMANICA;

EID: 0037285801     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37030     Document Type: Article

References (23)

1. Steinegger E, Hänsel R. Lehrbuch der Pharmakognosie und Phytopharmazie. 4. Ed Springer-Verlag, 1988: 252
2. Uphof JCTh. Dictionary of economic Plants. 2.Ed./Reprint. Lehre. Verlag von J Cramer, 1968: 284
3. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs. Fed. Proc. 1976; 35: 1332-8
4. Theisen C. Chemoprevention: What's in a name? J. Natl. Cancer Inst. 2001; 93: 743
5. Steele VE, Boone CW, Lubet RA, Crowell JA, Holmes CA, Sigman CC et al. Preclinical drug development paradigms for chemopreventives. Hematol./Oncol. Clin. North Am. 1998; 12: 943-61, v-vi
6. Alberts DS, Garcia DJ. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. J. Nutr. 1995; 125 (Suppl): 692S-7S
7. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 1997; 248: 188-90
8. Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal Eldeen A, Knauft J et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat. Res. 2002; (in press)
9. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76-85
10. Gerhäuser C, You M, Liu J, Moriarty RM, Hawthorne M, Mehta RG et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res. 1997; 57: 272-8
11. van Amsterdam FT, Roveri A, Maiorino M, Ratti E, Ursini F. Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic. Biol. Med. 1992; 12: 183-7
12. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20
13. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor-κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 2001; 276: 32008-15
14. Arisawa M, Morita N, Kondo Y, Takemoto T. Studies on constituents of Iris genus plants. IV. The constituents of Iris florentina L. (2). Chem. Pharm. Bull. 1973; 21: 2323-28
15. Kachroo PK, Razdan TK, Qurishi MA, Khuroo MA, Koul S, Dhar KL. Two isoflavones from Iris kashmiriana. Phytochemistry 1990; 29: 1014-16
16. Al-Khalil S, Al-Eisawi D, Kato M, Iinuma M. New isoflavones from Iris nigricans. J. Nat. Prod. 1994; 57: 201-5
17. Al-Khalil S, Al-Eisawi D. The chemotaxonomic profile of Iris atrofusca and I. atropurpurea. Bull. Fac. Pharm. (Cairo Univ.) 1995; 33 (special issue): 111-4
18. Aburjai T, Amro, Al-Khalil S, Al-Eisawi D. The chemical constituents of Iris petrana. Acta Technologiae et Legis Medicamenti 2000; 11: 137-45
19. Dewick PM. Isoflavonoids. In: Harborne JB, editor. The Flavonoids - Advances in Research since 1986 London: Chapman and Hall, 1994: 117-238
20. Pailer M, Franke F. Über Inhaltsstoffe der Iris germanica (Schwertlilie). Monatsh. Chem. 1973; 104: 1394-408
21. Ali AA, El-Emary NA, El-Moghazi M-A, Darwish FM, Frahm AW. Three isoflavonoids from Iris germanica. Phytochemistry 1983; 22: 2061-63
22. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW et al. Strategy and planning for chemopreventive drug development: clinical development plans II: Genistein. J. Cell. Biochem., Suppl. 1996; 26: 114-26
23. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 1994; 305: 253-64